Foghorn Therapeutics (NASDAQ:FHTX - Get Free Report) announced its earnings results on Thursday. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.13, Zacks reports. The company had revenue of $2.86 million during the quarter, compared to the consensus estimate of $8.56 million.
Foghorn Therapeutics Stock Performance
FHTX stock traded down $0.14 on Monday, reaching $4.38. The company's stock had a trading volume of 33,253 shares, compared to its average volume of 129,634. Foghorn Therapeutics has a 12-month low of $3.86 and a 12-month high of $10.25. The firm has a market cap of $243.58 million, a PE ratio of -2.28 and a beta of 3.13. The business has a fifty day simple moving average of $4.71 and a two-hundred day simple moving average of $6.71.
Analyst Upgrades and Downgrades
A number of research firms recently weighed in on FHTX. B. Riley started coverage on shares of Foghorn Therapeutics in a report on Thursday, January 30th. They issued a "buy" rating and a $10.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and set a $13.00 price objective on shares of Foghorn Therapeutics in a report on Friday. Finally, Jefferies Financial Group decreased their price objective on Foghorn Therapeutics from $18.00 to $14.00 and set a "buy" rating on the stock in a research note on Monday, December 16th. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $13.17.
Read Our Latest Stock Report on FHTX
About Foghorn Therapeutics
(
Get Free Report)
Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
See Also
Before you consider Foghorn Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Foghorn Therapeutics wasn't on the list.
While Foghorn Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
